AIM: To determine the tolerability and safety profile of a low-dose maintenance therapy with 6-TG in azathioprine (AZA) or 6-mercaptopurine (6-MP) intolerant inflammatory bowel disease (IBD) patients over a treatment period of at least 1 year. METHODS: Database analysis. RESULTS: Twenty out of ninety-five (21%) patients discontinued 6-TG (mean dose 24.6 mg; mean 6-TGN level 540 pmol/8 x 10(8) RBC) within 1 year. Reasons for discontinuation were GI complaints (31%), malaise (15%) and hepatotoxicity (15%). Hematological events occurred in three patients, one discontinued treatment. In the 6-TG-tolerant group, 9% (7/75) could be classified as hepatotoxicity. An abdominal ultrasound was performed in 54% of patients, one patient had splenomegaly. CONCLUSION: The majority of AZA or 6-MP-intolerant IBD patients (79%) is able to tolerate maintenance treatment with 6-TG (dosages between 0.3 and 0.4 mg/kg per d). 6-TG may still be considered as an escape maintenance immunosuppressant in this difficult to treat group of patients, taking into account potential toxicity and efficacy of other alternatives. The recently reported hepatotoxicity is worrisome and 6-TG should therefore be administered only in prospective trials.
AIM: To determine the tolerability and safety profile of a low-dose maintenance therapy with 6-TG in azathioprine (AZA) or 6-mercaptopurine (6-MP) intolerant inflammatory bowel disease (IBD) patients over a treatment period of at least 1 year. METHODS: Database analysis. RESULTS: Twenty out of ninety-five (21%) patients discontinued 6-TG (mean dose 24.6 mg; mean 6-TGN level 540 pmol/8 x 10(8) RBC) within 1 year. Reasons for discontinuation were GI complaints (31%), malaise (15%) and hepatotoxicity (15%). Hematological events occurred in three patients, one discontinued treatment. In the 6-TG-tolerant group, 9% (7/75) could be classified as hepatotoxicity. An abdominal ultrasound was performed in 54% of patients, one patient had splenomegaly. CONCLUSION: The majority of AZA or 6-MP-intolerant IBDpatients (79%) is able to tolerate maintenance treatment with 6-TG (dosages between 0.3 and 0.4 mg/kg per d). 6-TG may still be considered as an escape maintenance immunosuppressant in this difficult to treat group of patients, taking into account potential toxicity and efficacy of other alternatives. The recently reported hepatotoxicity is worrisome and 6-TG should therefore be administered only in prospective trials.
Authors: M C Dubinsky; S Lamothe; H Y Yang; S R Targan; D Sinnett; Y Théorêt; E G Seidman Journal: Gastroenterology Date: 2000-04 Impact factor: 22.682
Authors: Marla C Dubinsky; Eric A Vasiliauskas; Hardeep Singh; Maria T Abreu; Kostas A Papadakis; Tram Tran; Paul Martin; John M Vierling; Stephen A Geller; Stephan R Targan; Fred F Poordad Journal: Gastroenterology Date: 2003-08 Impact factor: 22.682
Authors: Luc J J Derijks; Dirk J de Jong; Lennard P L Gilissen; Leopold G J B Engels; Piet M Hooymans; Jan B M J Jansen; Chris J J Mulder Journal: Eur J Gastroenterol Hepatol Date: 2003-01 Impact factor: 2.566
Authors: Marla C Dubinsky; Edward J Feldman; Maria T Abreu; Stephan R Targan; Eric A Vasiliauskas Journal: Am J Gastroenterol Date: 2003-05 Impact factor: 10.864
Authors: Alexander Teml; Matthias Schwab; Daan W Hommes; Sven Almer; Milan Lukas; Thomas Feichtenschlager; Timothy Florin; Julia Seiderer; Wolfgang Petritsch; Bernd Bokemeyer; Wolfgang Kreisel; Klaus R Herrlinger; Peter Knoflach; Bruno Bonaz; Thomas Klugmann; Hans Herfarth; Nikolaus Pedarnig; Walter Reinisch Journal: Wien Klin Wochenschr Date: 2007 Impact factor: 1.704
Authors: Miloslav Kverka; Pavel Rossmann; Helena Tlaskalova-Hogenova; Klara Klimesova; Bindia Jharap; Nanne K de Boer; Rene M Vos; Adriaan A van Bodegraven; Milan Lukas; Chris J Mulder Journal: BMC Gastroenterol Date: 2011-05-05 Impact factor: 3.067
Authors: Melek Simsek; Berrie Meijer; Chris J J Mulder; Adriaan A van Bodegraven; Nanne K H de Boer Journal: Ther Drug Monit Date: 2017-12 Impact factor: 3.681
Authors: Melek Simsek; Debbie S Deben; Carmen S Horjus; Melanie V Bénard; Birgit I Lissenberg-Witte; Hans J C Buiter; Matthijs van Luin; Margien L Seinen; Chris J J Mulder; Dennis R Wong; Nanne K H de Boer; Adriaan A van Bodegraven Journal: Aliment Pharmacol Ther Date: 2019-05-16 Impact factor: 8.171